HRTX News and Press, Heron Therapeutics Inc. From 04/26/19

Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more ...

We select such investments on a long-term basis, weighing the same factors as would be involved in the purchase of 100% of an operating business: (1) favorable long-term economic characteristics; (2) competent and honest management; (3) purchase price attractive when measured against the yard...

SAN DIEGO , April 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...

Results from a postoperative pain study evaluating Heron Therapeutics' ( HRTX +0.7% ) HTX-011, together with an oral regimen of over-the-counter (OTC) painkillers acetaminophen and ibuprofen, for the management of postoperative pain in patients who had a bunion removed (bunionectomy) sh...

SAN DIEGO , March 11, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced re...

SAN DIEGO , March 4, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barr...

SAN DIEGO , Feb. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...

Heron Therapeutics (NASDAQ: HRTX ): Q3 GAAP EPS of -$0.63 misses by $0.17 . Revenue of $28.84M (+187.0% Y/Y) beats by $1.79M . Press Release More news on: Heron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

SAN DIEGO , Feb. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported fina...

SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barr...